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Abstract
Background: Ovarian cancer is the most lethal gynecologic malignancy, with the majority of cases diagnosed at an 
advanced stage when treatments are less successful. Novel serum protein markers are needed to detect ovarian cancer 
in its earliest stage; when detected early, survival rates are over 90%. The identification of new serum biomarkers is 
hindered by the presence of a small number of highly abundant proteins that comprise approximately 95% of serum 
total protein. In this study, we used pooled serum depleted of the most highly abundant proteins to reduce the 
dynamic range of proteins, and thereby enhance the identification of serum biomarkers using the quantitative 
proteomic method iTRAQ®.
Results: Medium and low abundance proteins from 6 serum pools of 10 patients each from women with serous 
ovarian carcinoma, and 6 non-cancer control pools were labeled with isobaric tags using iTRAQ® to determine the 
relative abundance of serum proteins identified by MS. A total of 220 unique proteins were identified and fourteen 
proteins were elevated in ovarian cancer compared to control serum pools, including several novel candidate ovarian 
cancer biomarkers: extracellular matrix protein-1, leucine-rich alpha-2 glycoprotein-1, lipopolysaccharide binding 
protein-1, and proteoglycan-4. Western immunoblotting validated the relative increases in serum protein levels for 
several of the proteins identified.
Conclusions: This study provides the first analysis of immunodepleted serum in combination with iTRAQ® to measure 
relative protein expression in ovarian cancer patients for the pursuit of serum biomarkers. Several candidate biomarkers 
were identified which warrant further development.
Background
Ovarian cancer results in over 14,000 deaths each year,
making it the fifth leading cause of cancer-related deaths
for women in the United States [1]. The high mortality
rate is due, in part, to the fact that over 80% of cases are
diagnosed after the cancer has spread beyond the ovary.
When ovarian cancer is detected early, the survival rate is
over 90% [2], highlighting the need for biomar kers for
early detection.
Current biomarkers for ovarian cancer detection and
screening are inadequate. The antigen CA125 is elevated
in the sera of most patients diagnosed with ovarian can-
cer [3,4]. However, CA125 lacks the sensitivity and speci-
ficity required for general screening, although it is
commonly used to monitor for recurrence. Many
researchers have attempted to find protein biomarkers
for ovarian cancer to replace or be used in conjunction
with CA125 in order to improve the sensitivity and speci-
ficity of diagnostic tests (reviewed in [5]).
Recently, methods for quantitative MS-based proteom-
ics have allowed the direct comparison of protein levels
present in control and diseased samples. Two technolo-
gies for quantitative proteomic studies are ICAT® [6] and
iTRAQ® [7], which employ differential labeling of up to
eight protein samples using stable isotope "chemical
tags," and analysis by mass spectrometry. Stewart et al.
[8] have used ICAT® to quantify differences between a cis-
platin-resistant and a cisplatin-sensitive ovarian cancer
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cell line. Gagne et al. [9] used iTRAQ® and 2-DE to evalu-
ate differential protein expression between an ovarian
cancer cell line of low malignant potential with a highly
proliferative cell line. Whether any of the proteins identi-
fied in these studies are present in patients' sera is not
known.
The MS identification of tumor-derived proteins in
plasma is hampered by the presence of a few highly abun-
dant proteins, which can mask the detection of low abun-
dance proteins which may be used as biomarkers. We
recently reported the depletion of high abundance pro-
teins from pooled serum samples from 60 patients with
serous ovarian carcinoma and 60 non-cancer controls
using immunoaffinity depletion columns. The remaining
medium and low abundance proteins were then subjected
to analysis by DIGE in order to identify proteins with
increased abundance in ovarian cancer sera relative to
control sera that may represent specific biomarkers [10].
In this study, we used iTRAQ® labeling to quantitate the
medium and low abundance proteins in serum for the
identification of candidate ovarian cancer biomarkers.
This analysis is the first to use immunodepletion in com-
bination with iTRAQ® labeling to look directly in sera for
ovarian cancer-specific biomarkers.
Results
Identification of candidate biomarkers by iTRAQ®
To reduce the dynamic range of proteins in the serum and
increase the likelihood of identifying medium and low
abundance serum proteins by mass spectrometry, we
used three commercial immunoaffinity depletion meth-
ods prior to proteomic analysis: the multiple affinity
removal system (MARS) column, the IgY-12 spin car-
tridge, or the IgY-12 HPLC column [10]. Serum samples
from 60 patients with serous ovarian carcinoma and 60
non-cancer controls were randomly combined into six
pools containing 10 patient samples each (e.g. C1 to C6
for the 60 cancer samples; N1 to N6 for the 60 non-cancer
control samples). In order to identify proteins that are dif-
ferentially expressed in ovarian cancer serum relative to
control, pooled, depleted sera were labeled with isobaric
tags using iTRAQ® for the relative quantitation of the
medium and low abundance proteins. A summary of the
five iTRAQ® experiments is shown in Table 1. Protein lev-
els were considered increased in sera from ovarian cancer
patients relative to non-cancer controls if the iTRAQ®
ratio of cancer/non-cancer (C/N) was ≥ 1.6 and the corre-
sponding non-cancer/non-cancer (N/N) ratio was
between 0.8 and 1.2. Fourteen proteins met these criteria
for overexpression in one or more experiments. The rela-
tive expression of these proteins for each serum pool is
displayed in Figure 1. The relative expression, statistical
parameters for quantitation, and the peptide information
for these proteins are provided in Additional files 1 and 2,
Tables S1 and S2.
iTRAQ® analysis of sera depleted by MARS
The medium and low abundance proteins from ovarian
cancer pool C1 and non-cancer pool N1 depleted using
the MARS column contained a total of 86 proteins identi-
fied with ≥ 95% confidence (Table 1). The five proteins
that met our criteria for an increase in relative abundance
in the cancer compared to the control were haptoglobin
(HAPT), orosomucoid-1 (ORM1), leucine-rich alpha-2-
glycoprotein-1 (LRG1), alpha-1 antichymotrypsin
(AACT), and fibrinogen-alpha (FGA; Figure 1; Additional
file 1, Table S1). Several proteins that were identified in
the MARS iTRAQ®  experiment by single peptide hits
were identified by at least two peptides, with significantly
increased ratios in the other iTRAQ® analyses (Figure 1;
Additional file 1, Table S1), including: LRG1, inter-alpha
globulin inhibitor-H3 (ITIH3), and proteoglycan-4
(PRG4). Although identified based on a single peptide,
the average iTRAQ® protein ratio for LRG1 was made
from three (replicate) peptide spectra, and the ratio was
~2.9-fold higher in ovarian cancer relative to control sera.
The iTRAQ® protein ratio for inter-alpha globulin inhibi-
tor-H3 was based on a single peptide, while no iTRAQ®
ratio was reported for PRG4 (Figure 1).
iTRAQ® analysis of sera depleted by the IgY12 spin column
Four serum pools (C4, C5, N3, and N6) depleted with the
IgY12 spin column were labeled with iTRAQ® mass tags
and analyzed by MS (Table 1). Of the 138 proteins that
were identified at ≥ 95% confidence, nine were overex-
pressed in the ovarian cancer compared to the control
serum pools (Table 1). Four of the five proteins that were
elevated in the MARS experiment were also increased in
this experiment. In addition, five new proteins with
increased expression in ovarian cancer sera were identi-
fied: alpha-1-antitrypsin (AAT), apolipoprotein E
(APOE), extracellular matrix protein-1 (ECM1), inter-
alpha globulin inhibitor-H3, orosomucoid-2 (ORM2; Fig-
ure 1; Additional file 1, Table S1). Orosomucoid-2 was
identified in the MARS depletion experiment, but did not
meet our criteria for increased relative expression in
ovarian cancer sera. Two proteins (serum amyloid P-
component (SAP) and ECM1) were identified based on
single peptide hits in this experiment, but were identified
by two or more peptides in at least one other experiment
(Additional files 1 and 2, Tables S1 and S2).
iTRAQ® analysis of sera depleted by the IgY12 HPLC
iTRAQ® analyses were performed on sera depleted by the
IgY12 HPLC column for all six pairs of cancer and control
serum pools, in three separate experiments (Table 1). The
maximum number of proteins identified at a ≥ 95% confi-Boylan et al. Proteome Science 2010, 8:31
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dence level was 134 (HPLC set 2). The number of pro-
teins that were overexpressed in the cancer compared to
the control serum pools ranged from two proteins (HPLC
set 3) to five proteins (HPLC set 2). Fibrinogen-alpha was
identified only in set 3, while lipopolysaccharide binding
protein-1 (LBP1) was identified only in sets 1 and 2,
based on a single peptide in each experiment (Figure 1;
Additional file 1, Table S1; spectra shown in Additional
file 3, Figure S1). In addition to LBP1, the overexpressed
proteins identified in the three IgY12 HPLC experiments
included four proteins identified by single peptides, how-
ever with the exception of LBP1, these were all identified
Table 1: Summary of the number of proteins identified in serum after abundant protein depletion
iTRAQ® Mass Tag Number of Proteins Identified
Confidence Level
Proteins Increased > 1.6 Fold†
Depletion Experiment 114 115 116 117 ≥ 99% ≥ 95%
MARS nd C1 N1 N1 75 86 5
IgY-12 Spin column C4 N3 C5 N6 114 138 9
IgY-12 HPLC set 1 N1 N4 C3 C6 88 107 5
IgY-12 HPLC set 2 N5 N6 C1 C4 109 134 4
IgY-12 HPLC set 3 N3 N2 C5 C2 87 113 2
C1-C6 correspond to six pools of ovarian cancer serum (10 patients each).
N1-N6 correspond to six pools of non-cancer control serum (10 patients each).
nd, not done
†C/N ratio > 1.6 and N/N ratio between 0.8 and 1.2
Figure 1 iTRAQ® Ratios for Selected Proteins Identified in Ovarian Cancer and Non-cancer Serum Pools. iTRAQ® ratios from all experiments for 
proteins that met our criteria for upregulation in at least one experiment (i.e. the ratio of cancer/non-cancer (C/N) was 1.6 or more and the correspond-
ing non-cancer/non-cancer (N/N) ratio was between 0.8 and 1.2). NQ, Not quantified. Gray boxes, not detected or quantified with 1 low confidence 
peptide. The p-value, EF and number of peptides for each protein, as well as the accession number, are listed in Additional Files Table 1. HAP, hapto-
globin; ORM1, orosomucoid 1; LRG, leucine rich alpha-2 glycoprotein 1; AAT, alpha-1 antitrypsin; AACT, alpha-1 antichymotrypsin; ITIH3, inter-alpha 
globulin inhibitor H3; APOE, apolipoprotein E; SAP, serum amyloid P component; LGALS3BP, galectin-3 binding protein; FGA, fibrinogen-alpha; PRG4, 
proteoglycan 4; ORM2, orosomucoid 2; LBP1, lipopolysaccharide binding protein 1; ECM1, extracellular matrix protein 1.
M
A
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Set
1
Set
2
Set
3
C N C1 C1 C4 C5 C4 C5 C3 C6 C3 C6 C1 C4 C1 C4 C5 C2 C5 C2 N1 N6 N4 N6 N2
N N N1 N1 N3 N3 N6 N6 N1 N1 N4 N4 N5 N5 N6 N6 N3 N3 N2 N2  N1  N3 N1 N5 N3
HAPT 2.4 1.4 1.6 2.0 1.8 2.4 1.7 2.3 18.1 17.4 12.5 16.3 2.1 2.4 1.3 1.5 13.8 2.8 8.9 1.9 1.2 1.0 1.4 1.5 1.7
ORM1 3.1 1.6 1.9 1.8 7.7 3.2 6.4 2.9 15.0 8.1 8.0 6.7 3.0 1.5 1.5 0.7 14.3 2.6 7.9 1.7 0.9 1.1 1.6 1.9 1.6
LRG1 3.1 1.1 2.8 3.1 4.7 3.1 4.2 3.0 4.0 4.2 3.5 4.5 5.4 4.0 2.8 2.0 2.8 2.2 3.1 2.6 1.1 1.0 1.1 1.7 0.9
AAT 1.8 0.9 3.5 2.2 1.8 0.8 1.8 0.8 1.6 12.1 0.3 2.1 0.7 0.5 2.4 1.6 7.0 3.7 1.9 1.0 0.6 0.9 6.7 0.3 3.8
AACT 2.0 0.9 2.1 1.8 2.2 1.7 2.4 1.9 1.5 1.8 1.7 2.5 2.5 2.4 2.4 2.4 1.7 1.3 2.2 1.8 0.8 0.9 0.9 0.9 0.7
ITIH3 1.7 1.0 1.4 1.1 1.9 1.6 1.8 1.4 2.0 1.5 2.1 1.8 1.7 1.8 1.7 1.8 2.0 2.1 1.3 1.4 0.7 1.1 1.0 0.9 1.6
APOE 1.5 1.2 1.3 1.2 2.2 1.4 2.2 1.6 3.1 1.9 1.6 1.8 1.2 0.8 0.9 0.6 2.0 2.1 1.0 1.1 0.9 0.9 1.2 1.2 1.9
SAP 1.3 0.8 2.9 1.0 1.5 1.0 1.2 0.8 1.0 1.1 1.4 1.7 1.8 1.9 1.9 2.0 0.8 0.8 1.3 1.3 0.5 1.2 0.8 0.8 0.6
LGALS3BP 1.3 1.0 0.4 1.3 0.4 1.3 0.7 0.9 1.0 1.5 1.8 1.9 1.7 1.8 2.1 2.4 1.0 1.2 1.0 0.7 1.0 2.0
FGA 4.7 1.1 3.8 5.2 4.7 2.1 6.5 3.1 17.5 4.7 7.9 2.7 1.1 0.7 2.4
PRG4 1.2 0.6 NQ NQ NQ NQ NQ NQ 3.5 1.2 6.4 NQ 0.8 0.9 3.2 4.0 0.2 1.2 0.2 1.2 NQ NQ NQ 0.2 1.0
ORM2 2.3 0.9 1.6 1.4 4.1 2.4 3.8 2.2 0.7 1.0
LBP1 1.8 1.0 1.5 2.0 1.6 2.2 1.6 2.8 NQ NQ 1.0 NQ
ECM1 1.6 1.3 1.5 1.7 1.6 1.8 2.1 1.6 1.2 0.9 0.9 1.6
<0.4 <0.8 1 >1.2 >1.6 >2.0 >3.0
Ratio
Median
Name
IgY HPLC Set 3 MARS IgY Spin IgY HPLC Set 1 IgY HPLC Set 2
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by 2 or more peptides in the other experiments (Addi-
tional file 1, Table S1). Galectin-3-binding protein
(LGALS3BP) was identified in each IgY12 HPLC experi-
ment; however, it met our criteria for increased expres-
sion only in HPLC set 2.
Comparison of Proteins Identified in Immunodepleted Sera
Proteins identified by MS/MS were compared among the
three immunodepletion methods. Figure 2A compares
the proteins identified in the three sets of experiments
run on IgY12 HPLC depleted sera. Of the 176 total pro-
teins identified, 40% of the proteins were identified in all
three experiments; and between 8 and 19% of the total
were unique to a single experiment.
Comparing the different immunoaffinity columns (Fig-
ure 2B) demonstrates that 25% of the 220 proteins were
identified by all three immunoaffinity depletion methods.
Not surprisingly, the proteins identified in serum
depleted by the two Ig Y12 column formats were more
similar to each other (i.e. 50% shared proteins) than to the
MARS column. About 40% more total proteins were
identified in the IgY12-depleted sera than in the MARS-
depleted sera; however, more immunoglobulins and com-
plement proteins were identified in IgY12-depleted sera
than in MARS-depleted sera (Additional file 2, Table S2).
Taken together, these data suggest that depletion of the
twelve most highly abundant serum proteins using the
IgY12 column is more effective at reducing the dynamic
range of serum proteins than the MARS column, and
r e s u l t s  i n  t h e  i d e n t i f i c a t i o n  o f  m o r e  m e d i u m  a n d  l o w
abundance serum proteins by MS. Overall, twice as many
proteins with increased expression in ovarian cancer sera
w e r e  i d e n t i f i e d  i n  t h e  I g Y 1 2 - d e p l e t e d  s e r a  t h a n  w e r e
identified in the MARS-depleted sera.
Validation of protein expression by immunoblotting
Results of the iTRAQ®  experiments were validated by
Western immunoblotting experiments (Figure 3). We
have previously shown by DIGE analysis of immunode-
pleted sera that levels of AACT and LRG1 expression are
increased in ovarian cancer sera, and validated this by
Western blot [10]. Immunodepleted serum was used for
the initial validation, as the presence of highly abundant
serum proteins interferes with detection of medium and
low abundance proteins by Western blot. Antibodies to
ECM1, LBP1, and alpha-1 antitrypsin were used to probe
Western blots of medium and low abundance proteins
from serum pools depleted by the IgY12 HPLC column.
We were particularly interested in validating the proteins
for which the peptide identification and/or quantitation
values were weak, as they represent proteins of very low
abundance that may be tissue leakage proteins or proteins
shed from the tumor. For example, ECM1 and LBP1 were
identified in two of five iTRAQ® experiments with 1 or 2
peptides (Additional file 1, Table S1). These proteins were
both increased by 1.6-fold or greater in the iTRAQ®
experiments, and were correspondingly increased in
ovarian cancer serum by Western blot (Figure 3). We also
validated the level of serum expression for alpha-1 antit-
rypsin. By Western blot, alpha-1 antitrypsin, a protein of
~52 kDa, is markedly more intense in all of the cancer
pools except C6. In an attempt to validate the iTRAQ®
quantitation for PRG4, two different commercial anti-
bodies were used to probe Western blots of the depleted
serum pools; however, the results of these blots were
inconclusive, likely due to extensive post-translational
modifications found in PRG4 [11].
Figure 2 Proteins identified in immunodepleted sera. Venn dia-
grams showing the number of total proteins identified by MS/MS (≥ 
95% confidence) in immunodepleted sera. (A) Proteins identified in the 
three sets of sera depleted by the IgY12 HPLC column. (B) Proteins 
identified in sera depleted by the MARS, IgY12 spin, and IgY12 HPLC 
columns. Identified proteins are listed in Additional file 2, Table S2.
Set 1
Set 3 Set 2
71
15
15 6
33 21 15
Proteins Identified in IgY12 HPLC depleted sera
MARS
IgY Spin IgY HPLC
55
14
6 11
57 24
53
Proteins Identified by Depletion Column
176 Proteins
Identified
220 Proteins
Identified A. B. Figure 3 Western blot validation of proteins overexpressed in 
cancer sera. (A) Western blots of 50 μg of medium and low abun-
dance proteins from each non-cancer (N1-N6) and cancer (C1-C6) se-
rum pool depleted by the IgY12 HPLC column were probed with the 
antibodies to ECM1, LBP1, and alpha-1 antitrypsin. (B) A replicate of the 
PVDF blot was stained for total protein with colloidal gold as a control 
for loading/transfer. Bracket indicates the approximate region of the 
blot where proteins of interest would be expected.Boylan et al. Proteome Science 2010, 8:31
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Discussion
We used the quantitative proteomic technique iTRAQ® to
analyze pooled, immunodepleted serum from ovarian
cancer patients and non-cancer controls for the discovery
of proteins that are present at increased levels in ovarian
cancer serum and may be candidates for biomarkers. For
our biomarker discovery experiments, we selected
patients with advanced disease under the assumption
that these patients may have higher levels of ovarian can-
cer proteins in their sera than patients with early stage
disease, thus increasing the likelihood of detecting ovar-
ian cancer specific biomarkers. The serum samples were
pooled in order to reduce variation between individual
samples and to increase the overall number of samples
tested. The technique of pooling samples prior to pro-
teomic analysis has been performed by others in similar
studies with body fluids [12-14].
Relative expression levels of 14 proteins in serum from
ovarian cancer patients were 1.6-fold or more higher than
the corresponding serum protein levels of healthy women
in at least one experiment. Nine proteins were identified
in all five iTRAQ® experiments, two proteins were identi-
fied in four experiments, two proteins were identified in
three experiments, and one protein was identified in two
experiments.
Several of the proteins identified in this study have pre-
viously been identified as potential ovarian cancer bio-
markers [15-18], demonstrating that iTRAQ® labeling of
serum can be used for the identification of differentially
expressed serum protein biomarkers. For example, hapto-
globin was first shown to be elevated in the sera of
women with ovarian cancer almost 40 years ago [16].
Others have confirmed this finding numerous times,
most recently by 2DE [19], and also with SELDI and
ELISA [17]. In addition to the iTRAQ® data presented
here, we have also shown by DIGE analysis that several
haptoglobin subunits are present at elevated levels in
ovarian cancer sera [10]. Serum amyloid A1 [20,21], and
C-reactive protein [22,23] have also previously been
shown to be elevated in ovarian cancer; in our analysis of
iTRAQ®  labeled sera these proteins had average C/N
ratios of 8.9 and 6.5 respectively, although the N/N peak
height was below the threshold for quantitation and not
reported by the ProteinPilot™ software. Consequently,
these proteins did not meet our criteria for inclusion in
Figure 1; however the relative expression, statistical
parameters for quantitation, and the peptide information
for these proteins are in Additional file 1, Table S1. C-
reactive protein was identified by a single peptide in sera
depleted by the MARS column; the spectrum for this
peptide is shown in Additional file 3, Figure S1.
Notably, we identified several candidate biomarker pro-
teins which have not been extensively studied. For exam-
ple, apolipoprotein-E (ApoE) was identified by multiple
peptides in all five iTRAQ® experiments, and was ~1.6-
fold elevated in the ovarian cancer serum pools.
Although commonly known for its role in lipid transport,
ApoE has previously been shown to be overexpressed in
ovarian cancer cells [24,25] where it is required for prolif-
eration and survival [25].
The protein LRG1 was determined to have robustly
increased levels of expression in ovarian cancer sera by
iTRAQ®. We have previously shown an increase in several
LRG1 isoforms in ovarian cancer serum by DIGE [10].
LRG1 expression in ovarian cancer sera was validated by
Western blot in the immunodepleted serum pools, and by
ELISA in individual, undepleted serum samples (data not
shown). Although LRG1 has been classified as an "acute
phase" protein, produced by the liver in response to
injury or infection [26,27], we have evidence that LRG1 is
also being produced by ovarian cancer cells and may con-
tribute to the increased levels of LRG1 found in patient
sera (manuscript in preparation). LRG1 levels have also
been shown to be elevated in the medium and low abun-
dance serum proteins of lung and pancreatic cancers [28-
30].
ECM1 was identified in two iTRAQ® experiments, with
an ovarian cancer-to-control ratio of ~1.6. The increase
in expression of ECM1 was validated by Western blot in
all of the ovarian cancer serum pools. ECM1 is a secreted
protein, which has been shown to be overexpressed in a
number of different epithelial cell tumors [31]. Interest-
ingly, ECM1 was identified in two proteomic analyses of
ovarian cancer ascites cells [32,33], and was also highly
enriched in the conditioned media from ovarian cancer
cell lines [33] and in chemoresistant ovarian tumor tissue
[34].
PRG4 was identified by iTRAQ®, with a relative protein
abundance in ovarian cancer-to-control of ~2.1. PRG4,
also known as megakaryocyte stimulating factor and
hemangiopoietin, is a multifunctional proteoglycan with
growth promoting properties in hemangioblasts [35]. It is
synthesized by chondrocytes and plays a role in joint
lubrication [36], however it is also synthesized by the
liver, heart, lung, and bone [37].
LBP1 was identified with an iTRAQ® ratio of 1.95 in
ovarian cancer vs. control sera, which was validated by
Western blot. LBP1 is proposed to play a role in immune
activation [38], however, the identification of LBP1 in
ovarian cancer ascites cells using MS [32,33] also sup-
ports a potential role in ovarian cancer.
We have previously reported the identification of can-
didate serum biomarkers for ovarian cancer by DIGE
analysis of pooled, depleted serum [10]. Four proteins
were shown to have increased levels in ovarian cancer
serum by both proteomic methods: haptoglobin, alpha-1
antichymotrypsin, serum amyloid P-component, and
LRG1. Five other proteins were found at increased levelsBoylan et al. Proteome Science 2010, 8:31
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in ovarian cancer serum by DIGE, while 12 additional
proteins were discovered by iTRAQ®, demonstrating that
these two techniques for identification of candidate bio-
markers are complementary.
Our study is the first to report immunoaffinity deple-
tion in combination with iTRAQ® labeling as a means to
quantitate serum proteins in ovarian cancer. Gagne et al.
[9] used the quantitative proteomic techniques of both
iTRAQ® and 2DE to compare two ovarian cancer cell
lines, one highly proliferative and the other with low
malignant potential, to identify proteins associated with
invasion and metastasis. Similarly, proteins associated
with prostate cancer progression were identified using
iTRAQ® labeling and comparison of highly and poorly
metastatic prostate cancer cell lines [39]. Other iTRAQ®
studies have compared tumor to normal tissue for bio-
marker discovery (e.g. endometrial, head and neck can-
cers [40-42], and hepatocellular carcinoma [43]). iTRAQ®
analysis of biofluids such as saliva [14] and cerebral spinal
fluid [12] has also been reported. Interestingly, a recent
quantitative proteomic analysis of ovarian tumor tissue
using ICAT labeling examined the relative expression of
tumor proteins in chemoresistant vs. chemosensitive
tumors, and found that five of the proteins identified in
this study [ECM1, LRG1, orosomucoid 1 (alpha-1-acid
glycoprotein) and alpha-1-antitrypsin] were all overex-
pressed in chemoresistant tumors [34], strengthening
their potential use as biomarkers.
In an iTRAQ® analysis of serum proteins in patients fol-
lowing brain injury, Hergenroeder et al. [44] identified
160 proteins (≥ 95% confidence) in sera immunodepleted
by the IgY12 column. Fifteen of the proteins identified
were increased in abundance compared to controls. The
relatively small number of serum proteins that they found
to be upregulated by iTRAQ® parallels the numbers seen
in our study . The proteins that were elevated in serum
from patients with traumatic brain injury included many
of the same serum proteins we found elevated in ovarian
cancer (e.g. haptoglobin, orosomucoids-1 and -2, alpha-1
antitrypsin, serum amyloid P-component, and alpha-1
antichymotrypsin), which suggests that these proteins are
not specific to ovarian cancer [44]. However, several of
these "acute phase" proteins have recently been shown to
discriminate between malignant and benign gynecologi-
cal disease, and thus may have a role in a "multi-analyte"
panel of ovarian cancer biomarkers [45]. In general, the
results indicate that the continued presence of highly
abundant serum proteins post-depletion, as well as the
presence of moderately abundant serum proteins, may
interfere with the detection of low abundance proteins
that are more specific to the disease.
Recently, Lin et al. [13] reported the identification of
serum biomarkers for ovarian cancer using depletion of
both high and moderately abundant proteins in combina-
tion with LC-MS/MS and ICAT® labeling. Using their
"deep depletion" method, they were able to identify 222
proteins, about three times as many as they found with
depletion of only the most abundant proteins. Similar to
our study, they found LRG1 levels were increased in ovar-
ian cancer serum. In contrast, they reported elevated lev-
els of a number of proteins (e.g., hemopexin, histidine-
rich glycoprotein, and vitronectin) that were identified in
our study but did not meet our criteria for overexpression
in ovarian cancer serum. This is potentially due to the
small number of samples (two pools of ten individuals in
each group) used in their study.
Conclusions
Using the iTRAQ®  labeling technology, we found an
increase in the levels of fourteen proteins in serum from
ovarian cancer patients relative to non-cancer controls,
demonstrating the utility of this technique for biomarker
discovery. In the future, it may be necessary to refine the
immunodepletion strategy in order to improve the MS
detection of low abundance proteins that are potentially
tumor-specific. Tonack et al. [46], recently reported a
protocol for iTRAQ® labeling of immunodepleted serum
and were able to identify 254 proteins, including tissue
leakage proteins present at very low abundance [46].
Although we were able to identify several promising can-
didates, the presence of moderately abundant serum pro-
teins limited our ability to find additional protein
biomarkers. The proteins ECM1, LBP1, and PRG4 all
warrant further investigation into their specificity as
potential biomarkers for ovarian cancer, using an ELISA
or other methods suitable for use in whole (undepleted)
serum. It will also be important to validate the candidate
biomarkers identified using a large population of individ-
ual serum samples, and to include samples from women
with early stage ovarian cancer, benign gynecological
conditions, and other types of solid tumors, as well as
healthy controls.
Methods
Patient samples
De-identified serum samples from 60 patients with
serous ovarian carcinoma and 60 female non-cancer con-
trols were obtained from the Gynecologic Oncology
Group (GOG) Tissue Bank. The majority of the ovarian
cancer serum samples were from patients with stage III
serous tumors (44 samples), nine had stage IV, and seven
had stage I and II tumors. The age of ovarian cancer
patients ranged from 35-85 years compared to 19-58
years for the non-cancer controls. Cancer and non-can-
cer control sera were separately pooled into six random
groups, each containing serum from ten patients (C1 toBoylan et al. Proteome Science 2010, 8:31
http://www.proteomesci.com/content/8/1/31
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C6 for the 60 cancer samples; N1 to N6 for the 60 non-
cancer control samples) as previously described [10].
Serum depletion
S e r u m  p o o l s  w e r e  d e p l e t e d  o f  t h e  s i x  o r  t w e l v e  m o s t
highly abundant serum proteins using one of three com-
mercially available immunoaffinity columns: the multiple
affinity removal system (MARS) spin column (Agilent
Technologies, Santa Clara, CA), the ProteomeLab IgY12
spin column (Beckman Coulter, Fullerton, CA) and the
ProteomeLab IgY12 High Capacity LC10 affinity column
(Beckman Coulter). Columns were run according to the
manufacturer's instructions [10].
iTRAQ® labeling
Peptides from 100 μg of each sample were labeled with 4-
plex iTRAQ® reagents according to the manufacturer's
procedure (Applied Biosystems Inc., Foster City, CA). For
the medium and low abundance proteins recovered from
the MARS column, one pool of ovarian cancer sera (C1)
was labeled with isobaric tag 115, while one pool of non-
cancer sera (N1) was divided into aliquots that were sepa-
rately labeled with isobaric tags 116 and 117 (Table 1).
Four sets of four samples (two ovarian cancer and two
non-cancer serum pools, depleted of high abundance
proteins by the IgY12 spin or IgY12 HPLC) were labeled
with the iTRAQ® isobaric reporter tags, 114, 115, 116, or
117. Labeled peptides from four samples were combined
into one tube and dried in vacuo. A SepPac™ C18 car-
tridge (Waters Corporation, Milford, MA) was used to
exchange the buffer, and to remove trypsin and the
hydrolyzed unbound iTRAQ® reagents from the labeled
peptides.
Strong cation exchange LC
Strong cation exchange (SCX) liquid chromatography
was used to separate the labeled peptides in the first
dimension as previously described [47]. Fractions were
collected at 3-min intervals and dried in vacuo.
Reversed phase LC-MS/MS analysis
Each dried SCX fraction with an A280 > 2 (fractions 13-
23) was reconstituted and injected onto a Dionex/LCP
Packings (Sunnyvale, CA) capillary LC system online
with a QSTAR Pulsar i mass spectrometer (Applied Bio-
systems) as previously described [47]. Product ion spec-
tra were collected in an information-dependent
acquisition (IDA) mode. IDA mode settings included
continuous cycles of one full-scan TOF MS from m/z 400
to 1,100 (1.5 sec) plus four product ion scans from m/z 50
to 2,000 (3 sec each). Precursor m/z values were selected
from a peak list automatically generated by Analyst QS
software (Applied Biosystems) from the TOF MS scan
during acquisition, starting with the most intense ion.
The data files have been deposited on the ProteomeCom-
mons.org Tranche network using the following hash:
yWlRCpE/tTaPaNyJWqYVXFNGWs/
H+29jMKH+aREtnW9HV/
fixhy94y6WSlkT+s1ue6ictzVQF7oP5PVtavlddRSir3sAA
AAAAAA92w==.
Data analysis and interpretation
ProteinPilot™ 2.0 software (Applied Biosystems), which
employs the Paragon™ search algorithm [48], was used for
peptide matching, protein identification, and relative pro-
tein quantitation. MS/MS data were searched against the
NCBI non-redundant human database (121306) plus
common contaminants (179 proteins, Thermo Scientific),
for a total of 289,431 proteins. Rates of false positive iden-
tifications were estimated using a concatenated reversed
sequence database [49]. False positive rates were < 0.3%
for all experiments. The search parameters were 95%
confidence for the detected protein threshold, trypsin
digestion, modification of cysteines by methylmethane-
thiosulfonate, biological modifications and thorough
search effort. The relative abundance of each peptide was
determined by ProteinPilot™ using the peak areas of sig-
nature ions from the iTRAQ®-labeled peptides. The Pro-
group™ Algorithm within the ProteinPilot™ v2.0 software
was used to compile the peptide identification into pro-
tein groups and to show protein-based ratios of relative
abundance. Peptides shared among related but distinct
proteins were not used for quantitation. Peptide MS/MS
for protein identifications inferred from single peptide
hits were manually inspected. In all cases except two, pro-
tein identifications made from single peptide hits in one
depletion experiment were made with two or more pep-
tides in at least one of the alternative depletion experi-
ments. Labeled spectra for these two proteins are
included as Additional file 3, Figure S1. Proteins were
considered overexpressed in ovarian cancer relative to
non-cancer control sera if the iTRAQ® ratio of C/N was
>1.6 and if the corresponding N/N ratio was between 0.8
and 1.2 in at least one experiment.
Western Blots
Fifty μg of IgY12 HPLC column depleted sera was sepa-
rated by SDS-PAGE and transferred to three replicate
PVDF membranes as described [10]. The blots were
probed with antibodies against human extracellular
matrix protein 1 (11521-1-AP, ProteinTech Group, Chi-
cago, IL); lipopolysaccharide binding protein-1 (AF870,
R&D Systems, Minneapolis, MN); alpha-1 antitrypsin
(mAb G11, Abcam, Cambridge, MA), and detected with a
horseradish peroxidase conjugated secondary antibody
and chemiluminescence (SuperSignal West Femto Maxi-
mum Sensitivity substrate; Pierce, Rockford, IL). Images
were collected by exposure to Kodak ×500 film (Midwest
Scientific, Valley Park, MO). A replicate PVDF blot wasBoylan et al. Proteome Science 2010, 8:31
http://www.proteomesci.com/content/8/1/31
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stained for total protein with colloidal gold (BioRad, Her-
cules, CA) as a loading control.
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